◎ Sugi Atlas

Atlas / Drug / Gemcitabine

Gemcitabine

drug
On this page

Also known as GemcitabinaGemzarLY-188011LY188011NSC-613327gemicitabine2',2'-difluorodeoxycytidine2',2'-difluoro-2deoxycytidineSID1248935552',2'-difluoro-2'-deoxycytidineGemcitabinGemcitabineGemcitabine HCl

Summary

Gemcitabine (CHEMBL888) is an approved small-molecule antineoplastic agent (ATC L01BC05) targeting RRM1 and RRM2; indicated across 114 conditions including neoplasm and exocrine pancreatic carcinoma; with CIViC clinical evidence for 39 variant-indication associations (e.g. RRM1 Underexpression in lung non-small cell carcinoma).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: L01BC05
  • Targets: 2 (RRM1, RRM2)
  • Indications: 114 conditions
  • Clinical trials: 1,976
  • Precision-oncology evidence (CIViC): 39 variant–indication associations
  • Chemistry: 263.2 Da · C9H11F2N3O4

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL888
NameGemcitabine
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID60750
ChEBICHEBI:175901
ATCL01BC05
Molecular formulaC9H11F2N3O4
Molecular weight263.2
InChIKeySDUQYLNIPVEERB-QPPQHZFASA-N

SMILES: C1=CN(C(=O)N=C1N)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F

IUPAC name: 4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one

ChEBI definition: A 2’-deoxycytidine having geminal fluoro substituents in the 2’-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.

Pharmacological roles (ChEBI): antineoplastic agent, antiviral drug, immunosuppressive agent, photosensitizing agent, DNA synthesis inhibitor, prodrug, EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor, radiosensitizing agent.

Other ChEBI roles (chemical / environmental): antimetabolite, environmental contaminant, xenobiotic.

Also known as: Gemcitabina, Gemcitabine, Gemzar, LY-188011, LY188011, NSC-613327, gemicitabine, 2’,2’-difluorodeoxycytidine, 2’,2’-difluoro-2deoxycytidine, gemcitabine, GEMCITABINE, SID124893555

Parent form; salt/anhydrous children: CHEMBL1637

Patent coverage: 44,499 distinct patent families (175,134 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
RRM1ribonucleotide reductase catalytic subunit M1Inhibition100% (common-essential)P23921
RRM2ribonucleotide reductase regulatory subunit M2Inhibition99.8% (common-essential)P31350

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Equilibrative nucleoside transporter 1, cGMP-inhibited 3’,5’-cyclic phosphodiesterase 3A, 3’,5’-cyclic-AMP phosphodiesterase 4D.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
SLC29A16.72IC50190nMCHEMBL_ACT_22751049

Target pathways

Aggregated over 2 target gene(s): RRM1, RRM2.

Top Reactome pathways

3 total, by targets touching each:

PathwayTargetsGenes
Interconversion of nucleotide di- and triphosphates2RRM1, RRM2
G1/S-Specific Transcription1RRM2
Transcriptional Regulation by E2F61RRM2

Dominant GO biological processes

GO termTargets
DNA repair2
ribonucleoside diphosphate metabolic process2
deoxyribonucleotide biosynthetic process2
2’-deoxyribonucleotide biosynthetic process2
protein heterotetramerization2
positive regulation of G1/S transition of mitotic cell cycle2
DNA synthesis involved in DNA repair1
pyrimidine nucleobase metabolic process1
mitochondrial DNA replication1
male gonad development1
response to ionizing radiation1
positive regulation of G2/M transition of mitotic cell cycle1
cell proliferation in forebrain1
retina development in camera-type eye1
positive regulation of G0 to G1 transition1

Indications & clinical

Indications

114 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
neoplasm4MONDO:0005070EFO:0000616
exocrine pancreatic carcinoma3MONDO:0005192EFO:0002618
non-small cell lung carcinoma3MONDO:0005233EFO:0003060
pancreatic neoplasm3MONDO:0021040EFO:0003860
biliary tract neoplasm3MONDO:0005304EFO:0003891
breast carcinoma3MONDO:0004989EFO:0000305
lymphoma3MONDO:0005062EFO:0000574
cholangiocarcinoma3MONDO:0019087EFO:0005221
sarcoma3MONDO:0005089EFO:0000691
ovarian carcinoma3MONDO:0005140EFO:0001075
urinary bladder neoplasm3MONDO:0004987EFO:0000294
ovarian neoplasm3MONDO:0021068EFO:0003893
cervical carcinoma3MONDO:0005131EFO:0001061
carcinoma3MONDO:0004993EFO:0000313
neoplasm of mature B-cells3MONDO:0004949EFO:0000096
hepatocellular carcinoma3MONDO:0007256EFO:0000182
Hodgkins lymphoma3MONDO:0004952EFO:0000183
peripheral T-cell lymphoma, not otherwise specified3MONDO:0004964EFO:0000211
angioimmunoblastic T-cell lymphoma3MONDO:0004977EFO:0000255
diffuse large B-cell lymphoma3MONDO:0018905EFO:0000403
mesothelioma3MONDO:0005065EFO:0000588
squamous cell carcinoma3MONDO:0005096EFO:0000707
squamous cell lung carcinoma3MONDO:0005097EFO:0000708
malignant pleural mesothelioma3MONDO:0005112EFO:0000770
breast neoplasm3MONDO:0021100EFO:0003869
nasopharyngeal neoplasm3MONDO:0005375EFO:0004252
gallbladder neoplasm3MONDO:0021253EFO:0004606
non-Hodgkin lymphoma3MONDO:0018908EFO:0005952
fallopian tube carcinoma3MONDO:0006206EFO:1000251
peritoneal neoplasm3MONDO:0006901EFO:1001100
gallbladder carcinoma3MONDO:0003220EFO:1001956
intrahepatic cholangiocarcinoma3MONDO:0003210EFO:1001961
soft tissue sarcoma3MONDO:0018078EFO:1001968
triple-negative breast carcinoma3MONDO:0005494EFO:0005537
urothelial carcinoma3MONDO:0040679EFO:0008528
hepatoblastoma3MONDO:0018666EFO:1000292
fallopian tube neoplasm3MONDO:0021092MONDO:0002158
ovarian cancer3MONDO:0008170MONDO:0008170
lung neoplasm3MONDO:0021117MONDO:0008903
follicular lymphoma3MONDO:0018906MONDO:0018906
nasal cavity and paranasal sinus lethal midline granuloma3MONDO:0006828MONDO:0019472
mature T-cell and NK-cell non-Hodgkin lymphoma3MONDO:0000430MONDO:0000430
head and neck squamous cell carcinoma3MONDO:0010150EFO:0000181
cervical adenocarcinoma3MONDO:0005153EFO:0001416
malignant pancreatic neoplasm3MONDO:0009831EFO:1000359
female reproductive organ cancer3MONDO:0001416EFO:1001331
pancreatic ductal adenocarcinoma3MONDO:0005184MONDO:0005184
nasopharyngeal carcinoma3MONDO:0015459MONDO:0015459
small cell lung carcinoma2MONDO:0008433EFO:0000702
adenocarcinoma2MONDO:0004970EFO:0000228
acute lymphoblastic leukemia2MONDO:0004967EFO:0000220
colorectal adenocarcinoma2MONDO:0005008EFO:0000365
germ cell tumor2MONDO:0005040EFO:0000514
leiomyosarcoma2MONDO:0005058EFO:0000564
osteosarcoma2MONDO:0009807EFO:0000637
renal cell carcinoma2MONDO:0005086EFO:0000681
melanoma2MONDO:0005105EFO:0000756
plasma cell myeloma2MONDO:0009693EFO:0001378
medulloblastoma2MONDO:0007959EFO:0002939
anaplastic large cell lymphoma2MONDO:0020325EFO:0003032
lung large cell carcinoma2MONDO:0003050EFO:0003050
testicular cancer2MONDO:0005447EFO:0005088
head and neck cancer2MONDO:0005627EFO:0006859
rectal cancer2MONDO:0006519EFO:1000657
mantle cell lymphoma2MONDO:0018876EFO:1001469
lung adenocarcinoma2MONDO:0005061EFO:0000571
anxiety2MONDO:0011918EFO:0005230
biliary tract disorder2MONDO:0004868EFO:0009534
bile duct neoplasm2MONDO:0021662MONDO:0003059
endometrium neoplasm2MONDO:0021251MONDO:0011962
T-cell non-Hodgkin lymphoma2MONDO:0015760MONDO:0015760
colonic neoplasm2MONDO:0005401MONDO:0021063
kidney cancer2MONDO:0002367MONDO:0002367
Ewing sarcoma2MONDO:0012817EFO:0000174
gastrointestinal stromal tumor2MONDO:0011719MONDO:0011719
central nervous system cancer2MONDO:0002714EFO:0000326
bone neoplasm2MONDO:0019060EFO:0003820
urethra neoplasm2MONDO:0021239EFO:0003846
bile duct carcinoma2MONDO:0005496EFO:0005540
bone cancer2MONDO:0002129EFO:1000350
olfactory neuroblastoma2MONDO:0006329EFO:1000407
colorectal neoplasm2MONDO:0005335MONDO:0005575
glioma2MONDO:0021042MONDO:0100342
leukemia1MONDO:0005059EFO:0000565
primary cutaneous T-cell non-Hodgkin lymphoma1MONDO:0000607EFO:0002913
synovial sarcoma1MONDO:0010434EFO:0001376
gastric neoplasm1MONDO:0021085MONDO:0001056
brain cancer1MONDO:0001657MONDO:0001657
acute myeloid leukemia1MONDO:0018874EFO:0000222
diffuse intrinsic pontine glioma0MONDO:0006033EFO:1000026

24 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 1,976.

Phase distribution

(phase/status distribution below is over 1,600 sampled trials of the 1,976 total).

PhaseTrials
PHASE2931
PHASE3355
PHASE1/PHASE2240
PHASE2/PHASE351
PHASE414
PHASE19

Top trials by phase / activity

NCTPhaseStatusTitle
NCT06457503PHASE4RECRUITINGA Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
NCT06820255PHASE4RECRUITINGDDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.
NCT07302841PHASE4NOT_YET_RECRUITINGTunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer
NCT00642733PHASE4TERMINATEDA Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
NCT01336192PHASE4UNKNOWNMaintenance Gemcitabine in the Chinese Advanced Lung Cancer
NCT01501136PHASE4UNKNOWNTreatment of Natural Killer/T Cell Lymphoma-I/II
NCT01501149PHASE4UNKNOWNTreatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ
NCT02299765PHASE4TERMINATEDIntercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC
NCT02812992PHASE4COMPLETEDGeriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients
NCT02996214PHASE4UNKNOWNPaclitaxel Liposome for Squamous Non-Small-cell Lung Cancer Study(LIPUSU)
NCT03071822PHASE4UNKNOWNCombination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas
NCT04040491PHASE4UNKNOWNPD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma
NCT04999878PHASE4UNKNOWNA Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.
NCT05723991PHASE4UNKNOWNStudy of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma
NCT02170090PHASE3ACTIVE_NOT_RECRUITINGAdjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer
NCT02446600PHASE3ACTIVE_NOT_RECRUITINGTesting the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02453282PHASE3ACTIVE_NOT_RECRUITINGPhase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
NCT02460887PHASE3ACTIVE_NOT_RECRUITINGThe Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT
NCT02486718PHASE3ACTIVE_NOT_RECRUITINGStudy to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
NCT02516241PHASE3ACTIVE_NOT_RECRUITINGStudy of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
NCT02542293PHASE3ACTIVE_NOT_RECRUITINGStudy of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
NCT02641847PHASE2/PHASE3ACTIVE_NOT_RECRUITINGTA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature
NCT02867865PHASE2/PHASE3ACTIVE_NOT_RECRUITINGPerioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers
NCT03003962PHASE3ACTIVE_NOT_RECRUITINGStudy of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
NCT03017326PHASE3ACTIVE_NOT_RECRUITINGPaediatric Hepatic International Tumour Trial
NCT03036098PHASE3ACTIVE_NOT_RECRUITINGStudy of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
NCT03164616PHASE3ACTIVE_NOT_RECRUITINGStudy of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
NCT03178552PHASE2/PHASE3ACTIVE_NOT_RECRUITINGA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT03257033PHASE3RECRUITINGIntra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
NCT03425643PHASE3ACTIVE_NOT_RECRUITINGEfficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
NCT03456076PHASE3ACTIVE_NOT_RECRUITINGA Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
NCT03478488PHASE3ACTIVE_NOT_RECRUITINGProgrammed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC
NCT03533582PHASE3ACTIVE_NOT_RECRUITINGCisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
NCT03661320PHASE3ACTIVE_NOT_RECRUITINGA Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
NCT03682068PHASE3ACTIVE_NOT_RECRUITINGStudy of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
NCT03703375PHASE3ACTIVE_NOT_RECRUITINGEfficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator’s Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma
NCT03732677PHASE3ACTIVE_NOT_RECRUITINGDurvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
NCT03734029PHASE3ACTIVE_NOT_RECRUITINGTrastuzumab Deruxtecan (DS-8201a) Versus Investigator’s Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
NCT03775265PHASE3ACTIVE_NOT_RECRUITINGChemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
NCT03800134PHASE3ACTIVE_NOT_RECRUITINGA Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

Clinical evidence (CIViC)

Variant × indication × effect (39 predictive associations from 41 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
RRM1 UnderexpressionLung Non-small Cell CarcinomaSensitivity/ResponseGemcitabine + CisplatinCIViC BEID2905 +1
RRM1 UnderexpressionPancreatic CancerSensitivity/ResponseGemcitabineCIViC BEID5506 +1
BRCA1 MutationPancreatic CancerSensitivity/ResponseCisplatin + Gemcitabine + VeliparibCIViC BEID5932
BRCA2 MutationPancreatic CancerSensitivity/ResponseCisplatin + Gemcitabine + VeliparibCIViC BEID5933
ERBB2 OverexpressionPancreatic CancerSensitivity/ResponseTrastuzumab + GemcitabineCIViC BEID5956
ERCC1 UnderexpressionLung Non-small Cell CarcinomaSensitivity/ResponseGemcitabine + CarboplatinCIViC BEID10142
ERCC1 UnderexpressionLung Non-small Cell CarcinomaSensitivity/ResponseCisplatin + GemcitabineCIViC BEID6431
FGFR3 MutationUrinary Bladder CancerSensitivity/ResponseCisplatin + GemcitabineCIViC BEID7566
IGF2 OverexpressionPancreatic AdenocarcinomaSensitivity/ResponseGanitumab + GemcitabineCIViC BEID7000
RRM1 UnderexpressionLung Non-small Cell CarcinomaSensitivity/ResponseCarboplatin + GemcitabineCIViC BEID10143
RRM1 UnderexpressionLung Non-small Cell CarcinomaSensitivity/ResponsePaclitaxel + Gemcitabine + CisplatinCIViC BEID12044
RRM1 UnderexpressionLung Non-small Cell CarcinomaSensitivity/ResponseGemcitabineCIViC BEID5530
RRM1 UnderexpressionLung Non-small Cell CarcinomaSensitivity/ResponsePaclitaxel + Vinorelbine + GemcitabineCIViC BEID5599
RRM1 UnderexpressionLung Non-small Cell CarcinomaSensitivity/ResponsePlatinum Compound + GemcitabineCIViC BEID6434
RRM1 UnderexpressionLung Non-small Cell CarcinomaSensitivity/ResponseCisplatin + GemcitabineCIViC BEID6436
SLC29A1 OverexpressionPancreatic AdenocarcinomaSensitivity/ResponseGemcitabineCIViC BEID10145
SMAD4 UnderexpressionLung Non-small Cell CarcinomaSensitivity/ResponseGemcitabineCIViC BEID6437
TP53 MutationPancreatic CancerSensitivity/ResponseGemcitabineCIViC BEID8282
WEE1 RS3910384Lung Non-small Cell CarcinomaSensitivity/ResponsePlatinum Compound + GemcitabineCIViC BEID814
XRCC1 R194WLung Non-small Cell CarcinomaSensitivity/ResponseDocetaxel + Gemcitabine + VinorelbineCIViC BEID659
ERCC1 OverexpressionLung Non-small Cell CarcinomaResistanceNedaplatin + GemcitabineCIViC BEID6435
KRAS Exon 2 MutationPancreatic CancerResistanceErlotinib + GemcitabineCIViC BEID1219
KRAS G12/G13Pancreatic AdenocarcinomaResistanceTrametinib + GemcitabineCIViC BEID622
ERCC1 ExpressionBladder CarcinomaPaclitaxel + Cisplatin + GemcitabineCIViC BEID6438
CIP2A UnderexpressionPancreatic Ductal AdenocarcinomaSensitivity/ResponseGemcitabineCIViC DEID1118
FANCC Loss-of-functionPancreatic CancerSensitivity/ResponseCisplatin + Melphalan + Chlorambucil + Mitomycin + GemcitabineCIViC DEID1307
HSPB1 EXPRESSIONPancreatic Ductal AdenocarcinomaSensitivity/ResponseGemcitabineCIViC DEID939
NRG1 ExpressionLung Non-small Cell CarcinomaSensitivity/ResponseCisplatin + Gemcitabine + Carboplatin + PaclitaxelCIViC DEID779
RB1 Loss-of-functionTriple-receptor Negative Breast CancerSensitivity/ResponseGemcitabineCIViC DEID12329
MAGEH1 EXPRESSIONBile Duct AdenocarcinomaResistanceGemcitabineCIViC DEID950

+9 more predictive associations (showing top 30 by level).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 90 clinical and 295 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

4 molecules share ≥1 primary target. Top 4 by shared-target count:

MoleculeSourceStatusShared targets
TRIAPINEChEMBLPhase 3RRM1, RRM2
ClofarabinePubChemApprovedRRM1, RRM2
FludarabinePubChemApprovedRRM1, RRM2
HydroxyureaPubChemApprovedRRM1, RRM2

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot